Global Trac Solutions, Inc. CEO, David Flores, sits down once again with Founder & CEO of The Third Wave, Paul F. Austin. The two begin their conversation with accessibility & affordability, concepts that are commonly overlooked in psychedelic medicine. They then dive into what it would take to create an infrastructure that ensures a very important segment of our society is able to gain access to the powerful, and profound benefits available through the use of psychedelic medicine.
Similar Posts
Extended-Release Ketamine Effective in Patients With Treatment-Resistant Depression
Ketamine may offer new hope for sufferers of treatment resistant depression via an extended-release oral administered option.
Psychedelic Twitter is Swarmed by Plug Bots
Psychedelic Twitter is a place for many interesting discussions, until you say “shrooms”, and then swarms of plug bots arrive
How to Microdose Psilocybin According to Paul Stamets: The Stamets Stack
Famed mycologist Paul Stamets recommends the Stamets Stack when microdosing psilocybin. Here’s how he plans and measures doses.
Single Dose of Psilocybin Strengthens Brain Connections in Mice, According to Yale Study
“It was a real surprise to see such enduring changes from just one dose of psilocybin,” says senior study author Alex Kwan.
First-of-Its-Kind Genetic Psychedelic Test Kit Now Available In U.S.
The first genetic psychedelic test kit is now available in the U.S. The kits are designed to help users know how they’ll respond to psychedelics.
Psychedelic Investment Platform Clarify Pharma to Go Public With £10.5 Million Valuation
The psychedelic investment platform Clarify Pharma is expecting to go public on the AQSE with a valuation of £10.5 million.